| 30/09/26 | 13:00:00 | 30 Sept 2026 | | Interim Results for the Six Months to June 30, 2026, and Business Update | GNW |
| 25/09/26 | 07:00:00 | 25 Sept 2026 | | The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer | GNW |
| 16/09/26 | 16:00:00 | 16 Sept 2026 | | Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial | GNW |
| 14/09/26 | 07:00:00 | 14 Sept 2026 | | Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee | GNW |
| 08/07/26 | 07:00:00 | 8 Jul 2026 | | Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors | GNW |
| 01/06/26 | 07:00:00 | 1 Jun 2026 | | Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 | GNW |
| 19/05/26 | 07:14:00 | 19 May 2026 | | Unaudited Preliminary Results for the Year Ended December 31, 2025 | GNW |
| 06/05/26 | 07:00:00 | 6 May 2026 | | Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 | GNW |
| 21/04/26 | 17:00:00 | 21 Apr 2026 | | Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform | GNW |
| 09/03/21 | 07:00:04 | 9 Mar 2021 | | Diagnostic Licensing Deal with Biokit | RNS |
| 08/03/21 | 07:00:13 | 8 Mar 2021 | | Rapid Antigen Test Detects SARS-CoV-2 Variants | RNS |
| 03/03/21 | 17:14:33 | 3 Mar 2021 | | Electronic Communications with Shareholders | RNS |
| 24/02/21 | 07:00:04 | 24 Feb 2021 | | Business Update | RNS |
| 22/02/21 | 07:00:08 | 22 Feb 2021 | | Re: Press Speculation | RNS |
| 18/02/21 | 07:00:03 | 18 Feb 2021 | | Phase I CTA for AVA6000 Approved by MHRA | RNS |
| 16/02/21 | 09:05:47 | 16 Feb 2021 | | Second Price Monitoring Extn | RNS |
| 16/02/21 | 09:00:35 | 16 Feb 2021 | | Price Monitoring Extension | RNS |
| 16/02/21 | 07:00:03 | 16 Feb 2021 | | Results of Initial Evaluation of SARS-CoV-2 LFT | RNS |
| 08/02/21 | 07:00:08 | 8 Feb 2021 | | Commercial Partnership with Mologic | RNS |
| 02/02/21 | 08:30:01 | 2 Feb 2021 | | Issue of Equity | RNS |
| 01/02/21 | 07:00:09 | 1 Feb 2021 | | AffyXell $7.3 Million Series A Financing | RNS |
| 29/01/21 | 11:00:01 | 29 Jan 2021 | | Issue of Equity | RNS |
| 28/01/21 | 07:00:07 | 28 Jan 2021 | | Collaboration Agreement with Bruker | RNS |
| 07/01/21 | 07:00:04 | 7 Jan 2021 | | License Agreement with POINT Biopharma Inc. | RNS |
| 05/01/21 | 11:05:29 | 5 Jan 2021 | | Second Price Monitoring Extn | RNS |
| 05/01/21 | 11:00:24 | 5 Jan 2021 | | Price Monitoring Extension | RNS |
| 23/12/20 | 07:00:02 | 23 Dec 2020 | | Submission of CTA for AVA6000 Pro-doxorubixin | RNS |
| 21/12/20 | 07:00:07 | 21 Dec 2020 | | License Agreement with Astrea Bioseparations | RNS |
| 23/11/20 | 09:05:17 | 23 Nov 2020 | | Second Price Monitoring Extn | RNS |
| 23/11/20 | 09:00:15 | 23 Nov 2020 | | Price Monitoring Extension | RNS |
| 23/11/20 | 07:00:06 | 23 Nov 2020 | | SARS-CoV-2 Rapid Antigen Test Update | RNS |
| 18/11/20 | 16:40:56 | 18 Nov 2020 | | Second Price Monitoring Extn | RNS |
| 18/11/20 | 16:36:06 | 18 Nov 2020 | | Price Monitoring Extension | RNS |
| 13/11/20 | 14:15:01 | 13 Nov 2020 | | Issue of Equity | RNS |
| 10/11/20 | 11:06:09 | 10 Nov 2020 | | Second Price Monitoring Extn | RNS |
| 10/11/20 | 11:00:39 | 10 Nov 2020 | | Price Monitoring Extension | RNS |
| 09/11/20 | 14:06:26 | 9 Nov 2020 | | Second Price Monitoring Extn | RNS |
| 09/11/20 | 14:01:22 | 9 Nov 2020 | | Price Monitoring Extension | RNS |
| 22/10/20 | 13:50:32 | 22 Oct 2020 | | Director/PDMR Shareholding | RNS |
| 08/10/20 | 09:00:02 | 8 Oct 2020 | | Issue of Equity | RNS |
| 30/09/20 | 14:05:53 | 30 Sept 2020 | | Second Price Monitoring Extn | RNS |
| 30/09/20 | 14:00:38 | 30 Sept 2020 | | Price Monitoring Extension | RNS |
| 30/09/20 | 10:35:34 | 30 Sept 2020 | | Launch of SARS-CoV-2 BAMS Research Test | RNS |
| 29/09/20 | 07:00:06 | 29 Sept 2020 | | Appointment of Joint Broker | RNS |
| 28/09/20 | 09:00:08 | 28 Sept 2020 | | Price Monitoring Extension | RNS |
| 28/09/20 | 07:00:06 | 28 Sept 2020 | | Interim Results for the Period Ended 30 June 2020 | RNS |
| 24/09/20 | 07:00:07 | 24 Sept 2020 | | Update on Integumen Collaboration | RNS |
| 14/09/20 | 07:00:10 | 14 Sept 2020 | | Notice of Results and Investor Presentation | RNS |
| 07/09/20 | 07:00:08 | 7 Sept 2020 | | Avacta to Launch SARS-CoV-2 ELISA Laboratory Test | RNS |
| 02/09/20 | 07:00:02 | 2 Sept 2020 | | Expansion of COVID-19 Test Manufacturing Capacity | RNS |
